Background: Although the frequencies of getting drug naive type 2 diabetes patients among all the diabetic patients are very low, nowadays it claims more attention in the treatment procedures of drug naive diabetic patients. But in Bangladesh, we have very few research-oriented data regarding the demographic, clinical and biochemical characteristics of drug naive type 2 diabetes patients. The aim of this study was to determine the demographic clinical and biochemical characteristics of drug naive type 2 diabetes patients of Bangladesh. Methods: This was an open label observational real-life study which was conducted in the chambers of the investigators in several places of Bangladesh as outdoor setting during the period from August 2020 to December 2020. In total, 250 patients with drug naive type 2 diabetes mellitus were enrolled as the study population. Proper written consents were taken from all the participants before starting data collection. A pre-designed questionnaire was used in patient data collection. All data were processed, analyzed and disseminated by MS Office and SPSS version as per need. Result: Two hundred and fifty (250) participants were selected as study population. The male-female ratio of the participants was 1.4:1. The highest number of participants was from 51 - 60 years’ age group (31.20%). The highest number of participants (41%) was with overweight (BMI: 25 - 30 kg/m2). Majority (65%) of the patients of this study suffered from diabetes for ≤5 years. The mean (±SD) SBP of the participants was 137.25 ± 17.50 mmHg and the mean (±SD) DBP of the participants was 85.16 ± 13.39 mmHg. We found the mean (±SD) fasting blood sugar (mg/dl), post prandial blood sugar (mg/dl), total cholesterol (mg/dl), triglycerides (mg/dl), HDL-Cholesterol (mg/dl), LDL-cholesterol (mg/dl), VLDL-cholesterol (mg/dl), uric acid (mg/dl), creatinine (mg/dl), urea (mg/dl), total bilirubin (mg/dl), direct bilirubin (mg/dl), SGOT (IU/L) and SGPT (IU/L) were 251.51 ± 112.08, 349.72 ± 128.68, 219.59 ± 68.25, 196.44 ± 94.34, 35.14 ± 11.85, 145.72 ± 64.33, 40.88 ± 18.12, 3.45 ± 1.51, 0.86 ± 0.37, 29.16 ± 9.81, 0.87 ± 0.4, 0.48 ± 0.4, 37.15 ± 10.9 and 35.83 ± 23.04 respectively. Conclusion: Obesity and hypertension demand more attention of diabetologists in diagnosis and treatment of patients or suspected patients of diabetes. Patients aged ≥ 50 years are most vulnerable and suspicious for diabetes. Besides age consequence habits of tobacco smoking, family history, smoking and HTN,
References
[1]
Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U. and Shaw, J.E. (2013) Global Estimates of Diabetes Prevalence for 2013 and Projections for 2035. Diabetes Research and Clinical Practice, 103, 137-149. https://doi.org/10.1016/j.diabres.2013.11.002
[2]
Whiting, D.R., Guariguata, L., Weil, C. and Shaw, J. (2011) IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030. Diabetes Research and Clinical Practice, 94, 311-321. https://doi.org/10.1016/j.diabres.2011.10.029
[3]
Hussain, A., Rahim, M., Azad Khan, A., Ali, S. and Vaaler, S. (2005) Type 2 Diabetes in Rural and Urban Population: Diverse Prevalence and Associated Risk Factors in Bangladesh. Diabetic Medicine, 22, 931-936. https://doi.org/10.1111/j.1464-5491.2005.01558.x
[4]
Swaminathan, K., Mathavan, A. and Jebamani, S. (2013) Diabetes and Coronary Artery Disease in South Asians. The British Journal of Diabetes & Vascular Disease, 13, 124-129. https://doi.org/10.1177/1474651413492177
[5]
Akter, S., Rahman, M.M., Abe, S.K. and Sultana, P. (2014) Prevalence of Diabetes and Prediabetes and Their Risk Factors among Bangladeshi Adults: A Nationwide Survey. Bulletin of the World Health Organization, 92, 204-213. https://doi.org/10.2471/BLT.13.128371
[6]
Bhowmik, B., Munir, S.B., Ahmed, K.R., Siddiquee, T., Diep, L.M., Wright, E., et al. (2013) Anthropometric Indices of Obesity and Type 2 Diabetes in Bangladeshi Population: Chandra Rural Diabetes Study (CRDS). Obesity Research & Clinical Practice, 8, e220-e229. https://doi.org/10.1016/j.orcp.2013.06.001
[7]
Rahim, M., Hussain, A., Azad Khan, A., Sayeed, M.A., Keramat Ali, S. and Vaaler, S. (2007) Rising Prevalence of Type 2 Diabetes in Rural Bangladesh: A Population-Based Study. Obesity Research & Clinical Practice, 77, 300-305. https://doi.org/10.1016/j.diabres.2006.11.010
[8]
Ramachandran, A., Mary, S., Yamuna, A., Murugesan, N. and Snehalatha, C. (2008) High Prevalence of Diabetes and Cardiovascular Risk Factors Associated with Urbanization in India. Diabetes Care, 31, 893-898. https://doi.org/10.2337/dc07-1207
[9]
Jandeleit-Dahm, K. and Cooper, M.E. (2002) Hypertension and Diabetes. Current Opinion in Nephrology and Hypertension, 11, 221-228. https://doi.org/10.1097/00041552-200203000-00014
[10]
Waeber, F.F. and Luis Ruilope, B. (2001) Diabetes and Hypertension. Blood Pressure, 10, 311-321. https://doi.org/10.1080/080370501753400610
[11]
Leung, G. and Lam, K. (2000) Diabetic Complications and Their Implications on Health Care in Asia. Hong Kong Medical Journal, 6, 61-68.
[12]
Hundal, R.S., Krssak, M., Dufour, S., et al. (2000) Mechanism by Which Metformin Reduces Glucose Production in Type 2 Diabetes. Diabetes, 49, 2063-2069. https://doi.org/10.2337/diabetes.49.12.2063
[13]
Basu, R., Shah, P., Basu, A., et al. (2008) Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People with Type 2 Diabetes. Diabetes, 57, 24-31. https://doi.org/10.2337/db07-0827
[14]
Turner, R.C., Cull, C.A., Frighi, V., Holman, R.R. and UK Prospective Diabetes Study (UKPDS) Group (1999) Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49). JAMA, 281, 2005-2012. https://doi.org/10.1001/jama.281.21.2005
[15]
Miccoli, R., Penno, G. and Del Prato, S. (2011) Multidrug Treatment of Type 2 Diabetes: A Challenge for Compliance. Diabetes Care, 34, S231-S235. https://doi.org/10.2337/dc11-s235
[16]
DeFronzo, R.A., Eldor, R. and Abdul-Ghani, M. (2013) Pathophysiologic Approach to Therapy in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Care, 36, S127-S138. https://doi.org/10.2337/dcS13-2011
[17]
Gallo, L.A., Wright, E.M. and Vallon, V. (2015) Probing SGLT2 as a Therapeutic Target for Diabetes: Basic Physiology and Consequences. Diabetes and Vascular Disease Research, 12, 78-89. https://doi.org/10.1177/1479164114561992
[18]
Grempler, R., Thomas, L., Eckhardt, M., et al. (2012) Mpagliflozin, a Novel Selective Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor: Characterization and Comparison with Other SGLT-2 Inhibitors. Diabetes, Obesity and Metabolism, 14, 83-90. https://doi.org/10.1111/j.1463-1326.2011.01517.x
[19]
(2021) Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2021. Diabetes Care, 44, S15-S33. https://doi.org/10.2337/dc21-S002
[20]
Ramachandran, A., Snehalatha, C. and Ma, R.C.W. (2014) Diabetes in South-East Asia: An Update. Diabetes Research and Clinical Practice, 103, 231-237. https://doi.org/10.1016/j.diabres.2013.11.011
[21]
Saquib, N., Khanam, M.A., Saquib, J., Anand, S., Chertow, G.M., Barry, M., et al. (2013) High Prevalence of Type 2 Diabetes among the Urban Middle Class in Bangladesh. BMC Public Health, 13, Article No. 1032. https://doi.org/10.1186/1471-2458-13-1032
[22]
Khanam, P.A., Mahtab, H., Ahmed, A.U., Sayeed, M.A. and Khan, A.A. (2008) In Bangladesh Diabetes Starts Earlier Now than 10 Years Back: A BIRDEM Study. Ibrahim Medical College Journal, 2, 1-3. https://doi.org/10.3329/imcj.v2i1.2922
[23]
Borah, M. and Goswami, R.K. (2017) Sociodemographic and Clinical Characteristics of a Diabetic Population at a Tertiary Care Center in Assam, India. Journal of Social Health and Diabetes, 5, 37-42.
[24]
Rana, H.M., Chavda, P., Rathod, C.C. and Mavani, M. (2015) Socio-Demographic and Anthropometric Profile of Diabetic Patients Attending Diabetes Clinic in Tertiary Care Hospital of Central Gujarat. National Journal of Community Medicine, 6, 554-557.
[25]
Mayer-Davis, E.J. and Costacou, T. (2001) Obesity and Sedentary Lifestyle: Modifiable Risk Factors for Prevention of Type 2 Diabetes. Current Diabetes Reports, 1, 170-176. https://doi.org/10.1007/s11892-001-0030-x